Polyrizon Ltd.
PLRZNASDAQHealthcareBiotechnology
Previous close
$10.30
−$0.19 · -1.81%
PLRZ company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
40
Expensive
Momentum
57
Neutral
Sentiment
58
Mixed
Risk resilience
50
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websitePolyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- IL
- CEO
- Tomer Izraeli
- Listed since
- Oct 29, 2024
- Employees
- 6
Market position
Day range
Current $10.30
52-week range
Current $10.30
- Open
- $10.625
- Previous close
- $10.49
- Volume
- 20.94K
- 0.4× average
- Average volume
- 52.74K
- Average daily volume
- Market cap
- 11.54M USD
- Beta
- -1.46
- Market reference 1
- 50-day average
- $12.3362
- -16.51% below average
- 200-day average
- $12.1149
- -14.98% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -2.95×
- P/B (TTM)
- 0.79×
- P/S (TTM)
- 0×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
Financial health
- Debt / equity
- 0×
PLRZ peers
Continue in GoAI
Research PLRZresearch.disclaimer